In a major step to reduce cervical cancer risks and boost human papillomavirus (HPV) vaccination coverage, Guyana’s Ministry of Health has introduced the “9-Valent vaccine”, also known as Gardasil 9, into the national healthcare system.

The vaccine, which has been widely available in the United States and other developed nations for years, protects against nine common strains of HPV that cause cervical cancer and is estimated to be about 90 per cent effective.

Speaking at the official launch ceremony held at the Diamond Regional Hospital, Minister of Health Dr Frank Anthony hailed the introduction of Gardasil 9 as a “scientific triumph”, describing the vaccine as safe, effective, and long-lasting. He highlighted that extensive clinical trials and global studies have shown the vaccine’s high success rate in building immunity and significantly reducing precancerous lesions.

The vaccine, produced by pharmaceutical company Merck, was procured at a significantly reduced cost through the Pan American Health Organisation’s (PAHO) Revolving Fund for Access to Vaccines. While the standard cost per dose stands at around USD$369, PAHO’s negotiation with Merck secured the vaccine for Guyana at only USD$15 per dose — a deal that resulted in estimated savings of nearly USD$17.7 million for the country.

“So, when you want to think about the partnership and what this fund can do, this is the value you get,” Minister Anthony remarked.
The rollout of Gardasil 9 forms part of Guyana’s commitment to achieving the World Health Organisation’s (WHO) target of eliminating cervical cancer by 2030 under its global 90-70-90 plan.

The strategy aims for 90 per cent of girls to be fully vaccinated by age 15, 70 per cent of women screened, and 90 per cent of women with pre-cancer treated or managed.
Minister Anthony disclosed that Guyana has already conducted approximately 12,000 HPV tests this year alone, with about 2,000 individuals testing positive — underscoring the urgent need for expanded vaccination and screening efforts.

Eligible females between the ages of nine and 45 are being encouraged to get vaccinated to lower their risk of infection.
This latest effort builds on other recent initiatives, including a $2.8 billion cervical screening programme launched in June 2024 to provide free screening for thousands of women aged 21 to 65, as well as the implementation of a new national action plan aimed at eradicating cervical cancer by 2030.